GKOS - Glaukos Corporation

NYSE - NYSE Delayed Price. Currency in USD
62.68
+0.29 (+0.46%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close62.39
Open62.97
Bid0.00 x 800
Ask0.00 x 900
Day's Range61.41 - 63.11
52 Week Range26.75 - 70.91
Volume291,268
Avg. Volume487,298
Market Cap2.258B
Beta (3Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)-0.40
Earnings DateMay 4, 2017 - May 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est68.13
Trade prices are not sourced from all markets
  • Markit2 days ago

    See what the IHS Markit Score report has to say about Glaukos Corp.

    # Glaukos Corp ### NYSE:GKOS View full report here! ## Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Negative Short interest is moderately high for GKOS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 19. ## Money flow ETF/Index ownership | Negative ETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding GKOS totaled $298 million. Additionally, the rate of outflows appears to be accelerating. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Have Insiders Been Selling Glaukos Corporation (NYSE:GKOS) Shares This Year?
    Simply Wall St.2 days ago

    Have Insiders Been Selling Glaukos Corporation (NYSE:GKOS) Shares This Year?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • Markit4 days ago

    See what the IHS Markit Score report has to say about Glaukos Corp.

    # Glaukos Corp ### NYSE:GKOS View full report here! ## Summary * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Negative Short interest is moderately high for GKOS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 19. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $615 million over the last one-month into ETFs that hold GKOS are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Tamarack Capital Management’s Return, AUM, and Holdings
    Insider Monkey8 days ago

    Tamarack Capital Management’s Return, AUM, and Holdings

    Tamarack Capital Management is a hedge fund that was founded by Mr. Justin John Ferayorni, its current Chief Investment Officer and Portfolio Manager. Before deciding to start his own firm, Mr. Ferayorni built up serious experience in investing, working as a Healthcare Analyst and Portfolio Manager, and later own as a Director of Research at […]

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Glaukos Corp.

    # Glaukos Corp ### NYSE:GKOS View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Negative Short interest is moderately high for GKOS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 19. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding GKOS are favorable, with net inflows of $3.19 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Hedge Funds Are Betting On Glaukos Corporation (GKOS)
    Insider Monkey28 days ago

    Hedge Funds Are Betting On Glaukos Corporation (GKOS)

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]

  • See what the IHS Markit Score report has to say about Glaukos Corp.
    Markit29 days ago

    See what the IHS Markit Score report has to say about Glaukos Corp.

    Short interest is moderately high for GKOS with between 10 and 15% of shares outstanding currently on loan. Over the last month, growth of ETFs holding GKOS is favorable, with net inflows of $2.99 billion. Index (PMI) data, output in the Healthcare sector is rising.

  • Business Wirelast month

    Glaukos Announces Participation in J.P. Morgan Healthcare Conference

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 9:30 a.m. PST in San Francisco. Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness.

  • Business Wirelast month

    Glaukos iStent inject® Implantation with Concomitant Cataract Surgery Provides Sustained Reduction in IOP and Medication Burden, According to New Study

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that a single-site international study of glaucoma subjects recently published in Ophthalmology and Therapy showed that the iStent inject® Trabecular Micro-Bypass System, combined with cataract surgery, achieved a 37% reduction in mean intraocular pressure (IOP) to 14.3 mmHg after three years of follow-up.

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for The Hackett Group, Green Plains, Malibu Boats, Hawaiian Electric Industries, Iridium Communications, and Glaukos — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Is Glaukos Corporation’s (NYSE:GKOS) CEO Pay Fair?
    Simply Wall St.2 months ago

    Is Glaukos Corporation’s (NYSE:GKOS) CEO Pay Fair?

    Thomas Burns became the CEO of Glaukos Corporation (NYSE:GKOS) in 2002. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we’ll look Read More...

  • See what the IHS Markit Score report has to say about Glaukos Corp.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Glaukos Corp.

    Short interest is moderate for GKOS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold GKOS had net inflows of $1.47 billion over the last one-month.

  • Business Wire2 months ago

    Glaukos Announces Participation in Piper Jaffray Healthcare Conference

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018, at 10:00 a.m. EST in New York City. Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of GKOS earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 Glaukos Corp Earnings Call

  • Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

    Glaukos (GKOS) delivered earnings and revenue surprises of -35.71% and 8.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Glaukos: 3Q Earnings Snapshot

    The San Clemente, California-based company said it had a loss of 19 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • Business Wire2 months ago

    Glaukos Corporation Announces Third Quarter 2018 Financial Results

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the third quarter ended September 30, 2018.

  • See what the IHS Markit Score report has to say about Glaukos Corp.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Glaukos Corp.

    Short interest is moderate for GKOS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding GKOS totaled $299 million.

  • See what the IHS Markit Score report has to say about Glaukos Corp.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Glaukos Corp.

    Short interest is moderate for GKOS with between 5 and 10% of shares outstanding currently on loan. The net inflows of $165 million over the last one-month into ETFs that hold GKOS are not among the highest of the last year and have been slowing.

  • Business Wire3 months ago

    Glaukos Technologies Featured in Presentations at 2018 American Academy of Ophthalmology Conference

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be featured in various presentations at the American Academy of Ophthalmology Annual Meeting on October 27-30, 2018 at ...

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Inogen and Glaukos

    NEW YORK, NY / ACCESSWIRE / October 23, 2018 / Major U.S. equities finished lower Monday on a combination of rising interest rates and global growth concerns. Investors await a flood of corporate earnings ...

  • Business Wire3 months ago

    Glaukos Corporation to Release Third Quarter 2018 Financial Results after Market Close on November 7

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release third quarter 2018 financial results after the market close on Wednesday, November 7, 2018. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on November 7, 2018.

  • Business Wire4 months ago

    Multiple Surgeon Presentations to Showcase Glaukos Products at 2018 European Society of Cataract and Refractive Surgeons Congress

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be included in various physician presentations at the 36th Congress of the European Society of Cataract and Refractive ...